Main branch restenosis at 1 year

Slides:



Advertisements
Similar presentations
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Advertisements

Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Tips and Pitfalls in Measurement of FFR during Bifurcation Stenting Nanjing first hospital Nanjing cardiovascular hospital Yefei Chenshaoliang Zhangjunjie.
DR ALEX CHASE REGIONAL HEART CENTRE MORRISTON SWANSEA SLIDE MATERIAL:PERSONAL COMMUNICATION WITH AUTHORS ABBOTT, BOSTON SCIENTIFIC, CORDIS, MEDTRONIC TCT.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
British Bifurcation Coronary Study Objective:To compare the outcome of 2 treatment strategies for bifurcation lesions. Study:Multicenter, randomized trial.
Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Importance Of Proximal Angle And Interpolated Minimal Luminal Diameter In Coronary Bifurcation Lesions Bhaktha M.D. Maddhavapeddy Aditya M.D. Maddury Jyotsna.
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and
Complex Coronary Cases
(DES)+BVS +DCB for long diffuse LAD disease
Strategy planning in coronary bifurcation stenting
CARIN Trial design: Patients undergoing coronary angiography were randomized in a 1:1:1:1 fashion to CMX mg/kg, 3.6 mg/kg, 4.8 mg/kg, or placebo.
ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.
The Tryton Bifurcation Trial:
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
DKCRUSH V Shao-Liang Chen, MD DKCRUSH V
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Subintimal Tracking and Reentry for CTO STAR Method
Stenting of Coronary Arteries in Non Stress/Benestent Disease
SIRIUS Trial: Diameter Restenosis
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
TAXUS II and IV: two-year follow-up
SKS Technique Clinical Case
Angiography-guided PCI
BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.
Primary endpoint at 1 year
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
REALITY: 8 month results
EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.
FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
EVERBIO II Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES.
Giuseppe Biondi Zoccai, MD
Presented at ACC 2003 Late Breaking Clinical Trials
ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.
Total lesions on MRI at 48 hours
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bifurcation Disease: Simulation Training Curriculum
Drug-eluting stents for in-stent restenosis
(p < for noninferiority)
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.
Presented at TCT 2006.
MACE: Death, MI or TLR at 5 years
Primary safety endpoint
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
The American College of Cardiology Presented by Dr. A. Abazid
Presentation transcript:

Main branch restenosis at 1 year DKCRUSH-VI Trial design: Patients with Medina 1,1,1 and 0,1,1 coronary bifurcation lesions undergoing stenting with a provisional side branch (SB) approach were randomly assigned in a 1:1 fashion to angiography-guided or FFR-guided groups. Patients were followed for 1 year. Results (p = 0.01) Side branch stenting in angiography vs. FFR arms: 38.1% vs. 25.9% (p = 0.01) In-segment restenosis in distal main vessel: 9.2% vs. 1.7%, p = 0.01; side branch vessel restenosis: 21.2% vs. 11.8%, p = 0.037 MACE: 18.1% vs. 18.1%, p = 1.0; MI: 13.8% vs. 11.9%, p = 0.74; TLR: 5.0% vs. 3.1%, p = 0.57; stent thrombosis: 1.3% vs. 0.6%, p > 0.05 % Conclusions FFR-guided strategy results in fewer stents and less angiographic restenosis than an angiography alone strategy in true bifurcation lesions where a provisional SB approach is pursued Clinical outcomes at 1 year were similar Appears to be a reasonable approach to ↓ stenting due to occulostenotic reflex in bifurcation lesions Main branch restenosis at 1 year Angiography-guided (n = 160) FFR- guided (n = 160) Presented by Dr. Shao Liang Chen at TCT 2014